Author: Benzinga Newsdesk | November 10, 2025 07:41am
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 23.84 percent. This is a 58.13 percent increase over losses of $(1.60) per share from the same period last year.